Several challenges are inherent in preclinical testing of nanotechnology: - Characterization of nanoparticles can be complex due to their small size and unique properties. - There is a lack of standardized testing protocols for nanomaterials. - The biological interactions of nanoparticles can differ significantly from bulk materials, making it difficult to predict their effects. - Ethical considerations in the use of animal models.
